Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Tectonic Therapeutic, Inc. (TECX)

Tectonic Therapeutic Q3 2026 net loss widens to $21.3 million from $19.0 million

Negative Impact 3 of 5 earnings Written later

Tectonic Therapeutic reported third-quarter 2026 results in an 8-K that furnished its press release. The net loss widened year over year, driven by higher research and development and general and administrative spending, while the company reported favorable Phase 1a safety and pharmacokinetic results for TX2100 and said cash should fund operations into Q1 2029.

Key points

  • Net loss of $21.3 million, or $1.08 per share, for the three months ended September 30, 2026, versus $19.0 million, or $1.02 per share, a year earlier.
  • Research and development expenses rose to $17.4 million from $16.9 million; general and administrative expenses rose to $6.0 million from $5.0 million.
  • Cash and cash equivalents were $234.7 million at September 30, 2026, down from $253.8 million at December 31, 2025.
  • Topline results from the APEX Phase 2 trial of TX45 in PH-HFpEF are expected by the end of January 2027.

The filing

CompanyTectonic Therapeutic, Inc. (TECX)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:28 PM ET
Accession number0001193125-26-449965

Items reported: 2.01 Acquisition or Disposition Completed

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.